Literature DB >> 15501543

Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.

Silvia Schenone1, Olga Bruno, Francesco Bondavalli, Angelo Ranise, Luisa Mosti, Giulia Menozzi, Paola Fossa, Sandra Donnini, Annalisa Santoro, Marina Ziche, Fabrizio Manetti, Maurizio Botta.   

Abstract

Synthesis and biological evaluation of a new class of 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives are reported. A preliminary cellular assay system using the tumor cell line A431 responding to epidermal growth factor (EGF) for its growth, shows that the new compounds are potent inhibitors of cell growth. The inhibition of tumor cell proliferation is not associated with blockage of EGF receptor (EGFR), but substantially due to the interference with the signalling pathway at the level of Src tyrosine kinase and at the level of the downstream effector signal mitogen activated protein kinases (MAPKs), ERK1-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501543     DOI: 10.1016/j.ejmech.2004.07.010

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Cytotoxic activities and DNA binding properties of 1-methyl-7H-indeno[1,2-b]quinolinium-7-(4-dimethylamino) benzylidene triflate.

Authors:  Wen Li; Yuan Yuan Ji; Jian Wen Wang; Yong Ming Zhu
Journal:  DNA Cell Biol       Date:  2012-01-25       Impact factor: 3.311

2.  Regioselective multi-component synthesis of 1H-pyrazolo[3,4-d]pyrimidine-6(7H)-thiones.

Authors:  Shirin Safaei; Iraj Mohammadpoor-Baltork; Ahmad Reza Khosropour; Majid Moghadam; Shahram Tangestaninejad; Valiollah Mirkhani
Journal:  Mol Divers       Date:  2012-08-29       Impact factor: 2.943

3.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

Review 4.  A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.

Authors:  Tanuja T Yadav; Gulam Moin Shaikh; Maushmi S Kumar; Meena Chintamaneni; Mayur Yc
Journal:  Front Chem       Date:  2022-06-13       Impact factor: 5.545

5.  Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.

Authors:  Michele Navarra; Marilena Celano; Jessica Maiuolo; Silvia Schenone; Maurizio Botta; Adriano Angelucci; Placido Bramanti; Diego Russo
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

6.  Design, Synthesis, and Antitumor Evaluation of Novel Pyrazolo[3,4-d]pyrimidine Derivatives.

Authors:  Manal M Kandeel; Lamia W Mohamed; Mohammed K Abd El Hamid; Ahmed T Negmeldin
Journal:  Sci Pharm       Date:  2012-06-25

7.  One-Flask Synthesis of Pyrazolo[3,4-d]pyrimidines from 5-Aminopyrazoles and Mechanistic Study.

Authors:  Wan-Ping Yen; Shuo-En Tsai; Naoto Uramaru; Hiroyuki Takayama; Fung Fuh Wong
Journal:  Molecules       Date:  2017-05-16       Impact factor: 4.411

8.  Novel pyrazolo[3,4-d]pyrimidine derivatives as potential antitumor agents: exploratory synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.

Authors:  Hai-Yun He; Jin-Ni Zhao; Ruo Jia; Ying-Lan Zhao; Sheng-Yong Yang; Luo-Ting Yu; Li Yang
Journal:  Molecules       Date:  2011-12-20       Impact factor: 4.411

9.  Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.

Authors:  Adel A-H Abdel-Rahman; Amira K F Shaban; Ibrahim F Nassar; Dina S El-Kady; Nasser S M Ismail; Samy F Mahmoud; Hanem M Awad; Wael A El-Sayed
Journal:  Molecules       Date:  2021-06-26       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.